EA
NBIX icon

Ellsworth Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Ellsworth Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$289K Sell
2,040
-37,587
-95% -$6.04M 0.05% 180
2026
Q2 		$6.82M Buy
+39,627
New +$5.88M 1.12% 35

Other funds holding NBIX

Ninety One (UK)
Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return
PBBUPS
PKO BP Bankowy Universal Pension Society Warsaw, Poland $340M AUM 228.33% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
IFM Investors
IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return
ACM
Argent Capital Management St Louis, Missouri $3.14B AUM 31.36% 1-Year Est. Return
RSC
Red Spruce Capital Berwyn, Pennsylvania $283M AUM 29.49% 1-Year Est. Return

Ellsworth Advisors's NBIX Position: Q3 2026 in Review

Ellsworth Advisors reduced its Neurocrine Biosciences (NBIX) stake by 95% in Q3 2026, selling an estimated $6.04M and leaving 2,040 shares worth $289K. The position accounts for 0.05% of the portfolio, ranked #180.

Ellsworth Advisors first reported a position in NBIX in Q2 2026 and has held it in 2 quarters since. The position peaked at $6.82M in Q2 2026. 76 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Ellsworth Advisors held 2,040 shares of Neurocrine Biosciences worth $289K as of Q3 2026.
  • Ellsworth Advisors sold 37,587 Neurocrine Biosciences shares in Q3 2026, an estimated $6.04M.
  • Neurocrine Biosciences made up 0.05% of Ellsworth Advisors's portfolio in Q3 2026, its #180 holding.
  • Ellsworth Advisors first reported a position in Neurocrine Biosciences in Q2 2026 and has held it in 2 quarters since.
  • Ellsworth Advisors's Neurocrine Biosciences position peaked at $6.82M in Q2 2026.
  • 76 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Ellsworth Advisors's 13F filing for Q3 2026, filed 15 Oct 2026.